Valuation: Alvotech

Market Cap 1.38B 1.2B 1.13B 1.02B 1.92B 133B 1.95B 13.2B 5.17B 66.36B 5.2B 5.09B 221B P/E 2026 *
14.6x
P/E 2027 * 8.46x
Enterprise Value 2.47B 2.13B 2.01B 1.82B 3.43B 236B 3.48B 23.53B 9.22B 118B 9.27B 9.07B 394B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.13x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.30%
1 week+3.09%
Current month+3.78%
1 month+13.78%
3 months+21.90%
6 months-3.52%
Current year-17.31%
1 week 36.1
Extreme 36.1
39.5
1 month 30.6
Extreme 30.6
40.65
Current year 27.5
Extreme 27.5
50.26
1 year 27.5
Extreme 27.5
86.22
3 years 27.5
Extreme 27.5
157
5 years 27.5
Extreme 27.5
157
10 years 27.5
Extreme 27.5
157
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%+3.09% - - 1.38B
-0.11%-1.67%+1.80%+19.90% 48.84B
+1.65%+4.54%+489.52%+625.46% 45.44B
+2.21%+2.74%+15.59%+91.20% 41.22B
+0.46%-0.59%+25.89%+13.28% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+1.09%-1.52% - - 16.25B
-1.01%-2.36%+27.72%+136.80% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-2.22%-0.07%+79.51%+41.68% 13.68B
Average -0.26%-0.78%+82.60%+126.69% 29.83B
Weighted average by Cap. +0.15%-0.84%+103.73%+153.69%

Financials

2026 *2027 *
Net sales 656M 566M 533M 484M 911M 62.84B 924M 6.25B 2.45B 31.43B 2.46B 2.41B 105B 779M 673M 633M 575M 1.08B 74.64B 1.1B 7.43B 2.91B 37.33B 2.92B 2.86B 124B
Net income 91.8M 79.28M 74.6M 67.8M 128M 8.8B 129M 875M 343M 4.4B 345M 337M 14.65B 151M 131M 123M 112M 210M 14.5B 213M 1.44B 565M 7.25B 568M 556M 24.16B
Net Debt 1.08B 936M 880M 800M 1.51B 104B 1.53B 10.33B 4.05B 51.92B 4.07B 3.98B 173B 1.06B 912M 858M 780M 1.47B 101B 1.49B 10.07B 3.95B 50.61B 3.96B 3.88B 169B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
19/08/26 SEK 38.40 -0.26% 7,760
17/08/26 SEK 38.50 -0.13% 13,488
14/08/26 SEK 38.55 +1.45% 33,130
13/08/26 SEK 38.00 +4.11% 15,258
12/08/26 SEK 36.50 -2.01% 643,066
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.880USD
Average target price
5.750USD
Spread / Average Target
+48.20%

Quarterly revenue - Rate of surprise